Bernardo Rapoport
Bernardo Rapoport
Extraordinary Professor of Immunology, University of Pretoria, South Africa
Adresse e-mail validée de rosebankoncology.co.za
Titre
Citée par
Citée par
Année
The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients
J Klastersky, M Paesmans, EB Rubenstein, M Boyer, L Elting, R Feld, ...
Journal of Clinical Oncology 18 (16), 3038-3051, 2000
12492000
Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
F Roila, J Herrstedt, M Aapro, RJ Gralla, LH Einhorn, E Ballatori, E Bria, ...
Annals of Oncology 21 (suppl_5), v232-v243, 2010
7932010
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing …
JM Nabholtz, HJ Senn, WR Bezwoda, D Melnychuk, L Deschenes, ...
Journal of Clinical Oncology 17 (5), 1413-1413, 1999
6341999
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
J Klastersky, J de Naurois, K Rolston, B Rapoport, G Maschmeyer, ...
Annals of Oncology 27 (suppl_5), v111-v118, 2016
3732016
2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F Roila, A Molassiotis, J Herrstedt, M Aapro, RJ Gralla, E Bruera, ...
Annals of Oncology 27 (suppl_5), v119-v133, 2016
3542016
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized …
BL Rapoport, K Jordan, JA Boice, A Taylor, C Brown, JS Hardwick, ...
Supportive Care in Cancer 18 (4), 423-431, 2010
2622010
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with …
M Marty, M Espie, A Llombart, A Monnier, BL Rapoport, V Stahalova
Annals of oncology 17 (4), 614-622, 2006
2032006
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
SM Grunberg, D Osoba, PJ Hesketh, RJ Gralla, S Borjeson, BL Rapoport, ...
Supportive care in cancer 13 (2), 80-84, 2005
1952005
Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score
A Uys, BL Rapoport, R Anderson
Supportive Care in Cancer 12 (8), 555-560, 2004
1912004
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
ME Lacouture, ML Maitland, S Segaert, A Setser, R Baran, LP Fox, ...
Supportive Care in Cancer 18 (4), 509-522, 2010
1862010
Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin …
R De Wit, J Herrstedt, B Rapoport, AD Carides, G Carides, M Elmer, ...
Journal of Clinical Oncology 21 (22), 4105-4111, 2003
1712003
The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based …
R de Wit, J Herrstedt, B Rapoport, AD Carides, J Guoguang-Ma, M Elmer, ...
European Journal of Cancer 40 (3), 403-410, 2004
1662004
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients …
BL Rapoport, MR Chasen, C Gridelli, L Urban, MR Modiano, ID Schnadig, ...
The Lancet Oncology 16 (9), 1079-1089, 2015
1542015
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and …
LS Schwartzberg, MR Modiano, BL Rapoport, MR Chasen, C Gridelli, ...
The Lancet Oncology 16 (9), 1071-1078, 2015
1442015
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art
SM Grunberg, D Warr, RJ Gralla, BL Rapoport, PJ Hesketh, K Jordan, ...
Supportive Care in Cancer 19 (1), 43-47, 2011
1142011
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety
M Aapro, A Carides, BL Rapoport, HJ Schmoll, L Zhang, D Warr
The oncologist 20 (4), 450-458, 2015
1052015
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group Performance Status 2 non–small-cell lung cancer …
C Langer, S Li, J Schiller, W Tester, BL Rapoport, DH Johnson
Journal of clinical oncology 25 (4), 418-423, 2007
922007
Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk‐index score with procalcitonin …
A Uys, BL Rapoport, H Fickl, PWA Meyer, R Anderson
European journal of cancer care 16 (6), 475-483, 2007
792007
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
Y Balagula, C Garbe, PL Myskowski, A Hauschild, BL Rapoport, ...
International journal of dermatology 50 (2), 129-146, 2011
762011
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy …
B Rapoport, D Chua, A Poma, S Arora, Y Wang, LE Fein
Supportive Care in Cancer 23 (11), 3281-3288, 2015
692015
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20